July 2011 Archives

Discovery of six mutated genes in head and neck squamous cell cancer provides an opportunity to develop customized treatment for the disease, researchers say.

"These findings should help us better treat patients by allowing us to take a more personalized approach than is currently possible with this cancer," said Jeffrey Myers, M.D., Ph.D., professor in MD Anderson's Department of Head and Neck Surgery. Myers is co-senior author of one of two papers published online on the Science Express feature of the journal Science Thursday.  

"Longer term, we'll see how patients with these genetic mutations do with our conventional treatments of surgery, radiation, chemotherapy or chemoradiation," Myers said. "This will help us identify groups of patients who need additional or different treatments."



Cancer evades or wards off attack by the immune system and even hijacks some aspects of the body's defenses against disease to thrive and grow.  As some cancer researchers experiment with vaccines and other ways to turn the immune system against tumors, other scientists pursue a greater understanding of the basic components of immunity to build a foundation for future progress.

Researchers led by Chen Dong, Ph.D, Ph.D., of MD Anderson's Department of Immunology and Center for Inflammation and Cancer, have discovered an off switch for the mass production of antibodies launched by the immune system in response to a specific infection or type of abnormal cell. 

The specialized regulatory T cell that they identified blocks the swift production of antibodies in structures called germinal centers.  "We have known that regulatory T cells defend against unwanted or exaggerated immune system responses, but the mechanism by which they accomplish this was not known," Dong said.


Read the News Release
: Specialized Regulatory T Cell Stifles Antibody Production Centers


GSBS Student Chases Details of Stray Neutrons in Proton Therapy

| Comments (2) | Trackbacks (0)
Rui Zhang and mentor Wayne Newhauser calculate wayward radiation dose

NewhauserZhangPublishing high-quality research is a major advantage for graduate students in today's climate of financial austerity and intense competition for grants and fellowships.

Rui Zhang, a doctoral student in The University of Texas Graduate School of Biomedical Sciences at Houston (GSBS), recently served as first author of a major paper in the journal Physics in Medicine and Biology--a top-tier publication in the field of radiation physics.

Guided by his advisor, Wayne Newhauser, Ph.D., associate professor in The University of Texas MD Anderson's Department of Radiation Physics, Zhang and his co-authors developed a new analytical model to calculate the dosage of stray neutrons that cancer patients are exposed to while undergoing proton therapy.

Search

Cancer Frontline on Twitter